Traditionally, the utility of antiasthmatic drugs has been assessed by improvements in clinical symptoms and respiratory parameters [such as forced expiratory volume in 1 sec (FEV1) and peak expiratory flow rate]. However, key opinion leaders at this year's European Respiratory Society meeting [Berlin, Germany; September 2001] suggested that quality of life (QOL) should form an important determinant in assessing a drug's utility.